Navigation Links
Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Date:4/8/2013

laboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulation of apoptosis, adhesion, and cell migration and homing. Through these multiple signals, BTK regulation helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a micro environment necessary for survival.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date five Phase III trials have been initiated with ibrutinib and a total of 26 trials are currently registered on www.clinicaltrials.gov.

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of eth
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics, Inc. Prices Public Offering of Common Stock
2. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
3. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
4. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
5. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
6. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
7. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
8. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
9. Hanger, Inc. Announces First Quarter 2013 Earnings Release And Conference Call
10. Sigma-Aldrich Announces Q1 2013 Earnings Conference Call
11. Uroplasty Announces CEO Resignation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014 Zynerba Pharmaceuticals , ... of innovative transdermal synthetic cannabinoid treatments, today announced that ... Annual Healthcare Conference 2014. The conference will be held ... in New York . Zynerba,s Chairman ... 4:50 pm on Tuesday, December 2. To ...
(Date:11/26/2014)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce the ... and Consultancy focusing on the active pharmaceutical ingredient (API) ... visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s ... – Forecast to 2020 , IQ4I ...
(Date:11/26/2014)... ANDOVER, Mass. , Nov. 25, 2014 ... Royal Philips (NYSE: PHG ... Food and Drug Administration (FDA) for its IQon ... spectral imaging. This first-of-its kind technology adds a new ... and offering the ability to characterize structures based on ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3
... , July 30 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, today announced that on July ... LLC, stating that PharmAthene is not in compliance with the continued ... NYSE Amex Company Guide, because it has stockholders, equity of less ...
... 30 Conatus Pharmaceuticals Inc. announced today that Conatus ... disclosed.  Conatus Pharmaceuticals is a privately-held drug development company focused on liver ... , ... Ph.D., the former CEO of Idun Pharmaceuticals, which was acquired by Pfizer ...
Cached Medicine Technology:PharmAthene Provides Update on NYSE Amex Listing Compliance Plan 2PharmAthene Provides Update on NYSE Amex Listing Compliance Plan 3Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary 2
(Date:11/27/2014)... New York, New York (PRWEB) November 27, 2014 ... behalf of individuals who were allegedly injured by the ... court, where a federal litigation is looking ahead to ... , According to a Scheduling Order issued earlier ... take place on December 16th at 10:00 a.m. Items ...
(Date:11/27/2014)... 27, 2014 “LAB.C” was featured on NewsWatch ... latest and coolest technology products available to consumers. Mallory Sofastaii, ... product review and shared with viewers the company offers ... Android devices. , Consumers love portability and functionality. A ... Case for the iPhone5 and 5S has a portable USB ...
(Date:11/27/2014)... HealthPostures, a leading national ... has announced that it has entered into a ... partnership will put HealthPostures' products into central Indiana’s ... addition to having its products sold through Commercial ... products with the business decision makers in the ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. ... of laughter as we enjoy the ugly sweater contest." ... from scratch. " It was a sight to see. ... ridiculous enough, the Christmas balls were faces of the staff ... in participating this year, it's simple to get in on ...
(Date:11/27/2014)... India (PRWEB) November 27, 2014 Ethane Web ... announced it will provide a 10% Christmas discount on PPC ... of December. The discount offer will begin on 1 December ... , About this offer, a PPC professional working at ... all, especially for small businesses, as this big discount would ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... A form of partial epilepsy associated with auditory ... disruption of brain development during early childhood, according to ... Medical Center (BIDMC). , Described in today,s Advance On-line ... provide the first genetic link between childhood brain development ...
... ... of Washington D.C. is business owner John Wahlquist of eMedicalSystems, Bremerton, Washington state. Author of ... unusual choice to retire his product and migrate his medical practices over to a new ... ...
... LOUISVILLE, Ky., Aug. 22 A top medical officer in the ... veterans service organizations can play a key role in suicide prevention ... coordinator, in pointing to the 5,000 self-inflicted deaths among veterans a ... to own up to that. There,s no reason any veteran in ...
... check-ups and communication with school staff , SATURDAY, Aug. 22 ... parents of children with asthma can prepare for flu season ... , "Good hygiene is the best and first line of ... frequent handwashing and covering your mouth when coughing or sneezing," ...
... CAESAREA, Israel, August 17 EndyMed Medical Ltd, an,innovative ... market, announced today the FDA clearance of the EndyMed,PRO(TM) ... rhytides. , The EndyMed PRO ... uses multiple, phase controlled sources, and is the,first product ...
... The nation,s home foreclosure epidemic may be taking its ... Nearly half of people studied while undergoing foreclosure reported ... major depression, according to new University of Pennsylvania School ... American Journal of Public Health. Many also ...
Cached Medicine News:Health News:Fragile period of childhood brain development could underlie epilepsy 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 3Health News:The American Legion Can Play Key Role in Vets' Suicide Prevention, Says VA 2Health News:Going Back to School With Asthma Takes Extra Work 2Health News:EndyMed Medical Receives FDA Clearance for Painless, Non-invasive Anti-Wrinkle Treatment System 2Health News:More than 1/3 of homeowners in foreclosure suffer from major depression, Penn study shows 2Health News:More than 1/3 of homeowners in foreclosure suffer from major depression, Penn study shows 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: